We found that CD90 was rarely observed in the early (30 weeks) and middle (40 weeks) stages of tumor development (data not shown), but was sporadically detected in the late (60 weeks) stage, which supports the notion that CD90 is a marker of HCC progression [17]. The gene discussed is THY1; the disease is neoplasm.